NCT06862206Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 3 Mar 2025
- Start date
- 11 Jul 2025
- Primary completion date
- 30 Jan 2028
- Lead sponsor
- AstraZeneca
- NCT number
- NCT06862206
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 11 Jul 2025 to the primary completion date, 30 Jan 2028
- 36 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with prior or ongoing treatment with benralizumab.
Other illness
- Known history of allergy or reaction to any component of the study treatment formulation.
- Malignancy of any kind.
Other
- -Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- Patients currently participating in any other clinical trial.
Who the study is looking for
- Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
- Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
- Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
- Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
Sex: All · Does not accept healthy volunteers
Sites (36)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.